▁Introduction 7.8203125
: 1.90625
<0x0A> 6.52734375
In 3.412109375
▁recent 3.603515625
▁years 0.27099609375
, 0.304443359375
▁substantial 8.203125
▁adv 3.115234375
anc 2.505859375
ements 0.00013172626495361328
▁have 0.35302734375
▁been 0.0633544921875
▁made 0.11785888671875
▁in 0.11865234375
▁the 0.62744140625
▁treatment 3.208984375
▁of 0.109130859375
▁mel 5.68359375
an 0.01430511474609375
oma 0.03839111328125
▁- 7.01953125
▁a 1.8076171875
▁highly 3.173828125
▁ag 0.71826171875
gress 0.0004279613494873047
ive 0.0001710653305053711
▁form 0.9892578125
▁of 0.002231597900390625
▁skin 0.0462646484375
▁cancer 0.0033626556396484375
. 0.6171875
▁Im 3.97265625
m 3.67578125
une 0.06793212890625
▁check 0.46923828125
point 0.0177154541015625
▁in 0.254150390625
hib 0.00018656253814697266
itors 0.0992431640625
▁and 3.26171875
▁adj 5.96484375
uv 0.0274658203125
ant 0.035675048828125
▁ther 0.81982421875
ap 0.994140625
ies 0.0004017353057861328
▁have 0.94384765625
▁emer 3.15625
ged 0.0003685951232910156
▁as 0.07861328125
▁ground 5.87890625
bre 0.42333984375
aking 1.7762184143066406e-05
▁treat 1.802734375
ments 0.0002903938293457031
▁that 1.748046875
▁offer 3.81640625
▁the 3.38671875
▁potential 0.7001953125
▁for 1.1669921875
▁long 1.8095703125
- 0.0276641845703125
term 0.1663818359375
▁rem 1.1982421875
ission 0.1068115234375
. 1.326171875
▁This 2.59375
▁ess 4.73046875
ay 0.0004911422729492188
▁expl 3.12890625
ores 0.0025310516357421875
▁the 0.240234375
▁imp 4.29296875
lications 0.0072021484375
▁of 0.0455322265625
▁these 0.2467041015625
▁ther 2.451171875
ap 0.0007748603820800781
ies 2.384185791015625e-06
▁for 0.9775390625
▁patients 1.40234375
▁at 6.01171875
▁different 3.1171875
▁stages 0.049591064453125
▁of 0.0311279296875
▁mel 1.068359375
an 9.274482727050781e-05
oma 0.000823974609375
, 1.1455078125
▁foc 4.12109375
using 0.00489044189453125
▁on 0.1317138671875
▁their 2.12890625
▁impact 2.041015625
▁on 0.045379638671875
▁impro 5.73828125
ving 0.00201416015625
▁surv 1.25
ival 0.012542724609375
▁rates 0.177001953125
. 2.947265625
▁To 5.6875
▁further 3.435546875
▁illustrate 3.40234375
▁these 1.7490234375
▁adv 2.55078125
anc 0.2452392578125
ements 4.9114227294921875e-05
, 0.12091064453125
▁the 2.35546875
▁case 3.634765625
▁of 0.625
▁Mr 4.1640625
. 0.11962890625
▁B 4.203125
, 0.91845703125
▁a 0.425537109375
▁mel 3.443359375
an 0.0002340078353881836
oma 0.0007281303405761719
▁patient 0.09808349609375
, 1.4365234375
▁will 0.875
▁be 0.05548095703125
▁used 0.9560546875
▁as 1.0751953125
▁an 0.365234375
▁example 0.1767578125
. 0.38427734375
<0x0A> 0.482666015625
Body 10.3203125
: 0.2222900390625
<0x0A> 5.375
The 2.724609375
▁introduction 2.4609375
▁of 1.1142578125
▁imm 0.226318359375
une 0.14111328125
▁check 0.00449371337890625
point 0.00399017333984375
▁in 0.0102386474609375
hib 3.5762786865234375e-06
itors 0.01568603515625
, 2.41015625
▁such 0.254638671875
▁as 0.0001894235610961914
▁p 1.7705078125
emb 0.0031604766845703125
rol 0.0004286766052246094
iz 0.0006856918334960938
um 0.0007262229919433594
ab 0.00022041797637939453
▁and 0.626953125
▁n 0.3291015625
iv 0.00035953521728515625
ol 0.0010519027709960938
um 0.0009860992431640625
ab 0.0001341104507446289
, 0.020233154296875
▁marks 8.328125
▁a 0.163330078125
▁significant 0.62109375
▁shift 0.982421875
▁in 0.02508544921875
▁mel 1.8642578125
an 4.5299530029296875e-05
oma 0.00015270709991455078
▁treatment 0.0931396484375
. 0.1514892578125
▁These 0.18701171875
▁in 5.453125
hib 0.0007834434509277344
itors 0.00568389892578125
▁target 1.298828125
▁specific 2.345703125
▁check 2.34375
points 0.204833984375
▁on 1.546875
▁imm 1.5625
une 0.0008344650268554688
▁cells 0.0550537109375
, 1.0185546875
▁effectively 4.14453125
▁blocking 3.37890625
▁the 1.447265625
▁signals 2.806640625
▁that 0.0208892822265625
▁prevent 1.2373046875
▁T 2.919921875
- 0.53662109375
cell 0.0130615234375
s 0.0625
▁( 5.99609375
a 0.6328125
▁type 0.08123779296875
▁of 0.0003197193145751953
▁imm 0.7060546875
une 0.0021877288818359375
▁cell 0.09661865234375
) 0.0166778564453125
▁from 0.0021991729736328125
▁attack 0.5029296875
ing 6.92605972290039e-05
▁cancer 0.320556640625
▁cells 0.142822265625
. 0.03857421875
▁As 1.8173828125
▁a 0.026031494140625
▁result 0.0017490386962890625
, 0.0219879150390625
▁the 1.3037109375
▁body 1.9296875
' 0.265380859375
s 7.152557373046875e-05
▁imm 0.18017578125
une 0.0005450248718261719
▁system 0.0704345703125
▁is 0.1807861328125
▁react 6.23828125
iv 1.5020370483398438e-05
ated 6.222724914550781e-05
, 0.73681640625
▁en 2.9921875
han 3.15234375
cing 2.86102294921875e-06
▁its 0.5478515625
▁ability 0.09686279296875
▁to 9.34600830078125e-05
▁fight 1.1728515625
▁mel 2.548828125
an 2.8371810913085938e-05
oma 0.00295257568359375
. 0.2362060546875
▁Several 5.91015625
▁studies 0.677734375
▁have 0.0197906494140625
▁reported 3.84765625
▁remarkable 3.578125
▁response 3.349609375
▁rates 0.0021800994873046875
▁to 2.537109375
▁imm 0.8369140625
une 0.03253173828125
▁check 0.007770538330078125
point 0.00457000732421875
▁in 0.015777587890625
hib 1.2993812561035156e-05
itors 0.02471923828125
, 0.30908203125
▁with 0.2352294921875
▁a 3.642578125
▁subset 4.21875
▁of 0.01043701171875
▁patients 0.0200042724609375
▁ach 1.021484375
ieving 5.435943603515625e-05
▁dur 2.306640625
able 0.00041747093200683594
▁long 2.966796875
- 0.0027637481689453125
term 0.0088958740234375
▁rem 0.09063720703125
ission 0.179931640625
. 0.16259765625
<0x0A> 0.65283203125
Pat 5.54296875
ients 0.024261474609375
▁with 0.48876953125
▁advanced 1.1640625
▁or 2.23046875
▁met 0.1802978515625
ast 0.00012385845184326172
atic 0.005092620849609375
▁mel 0.05755615234375
an 2.872943878173828e-05
oma 0.0012102127075195312
▁have 1.8359375
▁particularly 3.458984375
▁benef 0.0789794921875
ited 0.1722412109375
▁from 0.002727508544921875
▁imm 1.3828125
une 0.0377197265625
▁check 0.005619049072265625
point 0.001392364501953125
▁in 0.0136871337890625
hib 5.602836608886719e-06
itors 0.08795166015625
. 0.31884765625
▁Research 5.65234375
, 9.2109375
▁including 1.1796875
▁clin 3.8203125
ical 0.00023615360260009766
▁tri 0.06134033203125
als 1.811981201171875e-05
, 0.293701171875
▁consist 6.26171875
ently 0.0006384849548339844
▁demonstrate 2.181640625
▁improved 2.93359375
▁overall 0.79296875
▁surv 0.043670654296875
ival 0.00017690658569335938
▁rates 0.97119140625
▁and 1.6650390625
▁pro 1.3447265625
gression 0.0003714561462402344
- 0.0036029815673828125
free 0.0005679130554199219
▁surv 0.05010986328125
ival 0.0002853870391845703
▁in 2.5
▁patients 0.7744140625
▁treated 0.52978515625
▁with 0.001270294189453125
▁these 0.61474609375
▁in 1.5546875
hib 0.00028777122497558594
itors 0.0007662773132324219
▁compared 0.95751953125
▁to 0.05682373046875
▁traditional 2.4140625
▁chem 1.2998046875
other 0.0011501312255859375
apy 0.1722412109375
. 0.6044921875
▁For 2.0859375
▁instance 1.095703125
, 0.0004749298095703125
▁a 1.005859375
▁study 0.88134765625
▁published 0.89501953125
▁in 0.0167388916015625
▁the 0.59423828125
▁New 0.362060546875
▁England 0.0003600120544433594
▁Journal 0.0013475418090820312
▁of 0.0007085800170898438
▁Medicine 0.0012121200561523438
▁reported 1.46875
▁a 1.234375
▁median 0.86572265625
▁overall 0.1837158203125
▁surv 0.0015840530395507812
ival 5.817413330078125e-05
▁of 0.1207275390625
▁ 0.0859375
7 4.640625
2 3.44921875
. 0.84619140625
1 2.67578125
▁months 0.057830810546875
▁in 0.78173828125
▁patients 0.10772705078125
▁receiving 2.34375
▁p 0.7763671875
emb 0.0036945343017578125
rol 5.412101745605469e-05
iz 5.8531761169433594e-05
um 0.0003440380096435547
ab 3.7550926208496094e-05
, 1.177734375
▁compared 0.297119140625
▁to 0.0185394287109375
▁ 0.08660888671875
1 2.3359375
6 2.765625
. 0.087890625
0 3.916015625
▁months 0.00577545166015625
▁in 0.25830078125
▁those 0.38671875
▁receiving 0.1826171875
▁chem 0.46875
other 0.0009431838989257812
apy 0.0004684925079345703
. 0.332275390625
▁This 2.6953125
▁presents 8.8984375
▁a 0.2030029296875
▁significant 0.52294921875
▁adv 2.603515625
ancement 0.00023937225341796875
, 4.27734375
▁offering 2.634765625
▁new 2.537109375
▁hope 0.052734375
▁to 0.80859375
▁patients 0.309326171875
▁who 2.201171875
▁were 1.8544921875
▁previously 0.1278076171875
▁faced 1.84765625
▁with 0.0003056526184082031
▁limited 0.484619140625
▁treatment 0.15625
▁options 0.0012598037719726562
▁and 2.390625
▁poor 0.775390625
▁pro 0.42333984375
gn 0.00020492076873779297
osis 0.865234375
. 0.014984130859375
<0x0A> 0.03558349609375
F 4.828125
ur 0.07696533203125
ther 5.960464477539062e-07
more 0.1236572265625
, 0.00015926361083984375
▁the 1.2080078125
▁use 1.3671875
▁of 0.00017189979553222656
▁imm 0.9150390625
une 0.0235443115234375
▁check 0.003040313720703125
point 0.00446319580078125
▁in 0.0009675025939941406
hib 1.7881393432617188e-06
itors 0.001201629638671875
▁as 4.1171875
▁adj 0.311767578125
uv 0.006420135498046875
ant 0.01110076904296875
▁ther 0.039306640625
ap 1.40625
ies 1.2278556823730469e-05
▁in 1.984375
▁patients 0.64453125
▁with 0.155029296875
▁high 0.92822265625
- 0.0259552001953125
ris 0.0005431175231933594
k 9.298324584960938e-06
▁mel 0.47509765625
an 2.7894973754882812e-05
oma 0.00811767578125
▁who 6.06640625
▁have 0.1776123046875
▁under 0.1551513671875
g 5.173683166503906e-05
one 8.821487426757812e-06
▁surg 0.24853515625
ical 1.0537109375
▁res 0.62353515625
ection 0.0012187957763671875
▁has 0.705078125
▁shown 2.41015625
▁prom 0.380615234375
ising 2.0384788513183594e-05
▁results 0.061767578125
. 0.04833984375
▁Ad 2.0703125
j 0.0005192756652832031
uv 0.000537872314453125
ant 0.0007781982421875
▁ther 0.04351806640625
apy 0.51708984375
▁is 1.10546875
▁admin 2.875
ister 1.7881393432617188e-05
ed 0.0001850128173828125
▁after 0.425537109375
▁cur 5.4375
ative 0.0003464221954345703
▁surg 0.740234375
ery 0.1048583984375
▁to 0.3759765625
▁eliminate 4.12109375
▁any 0.1690673828125
▁remaining 0.242919921875
▁und 7.6640625
et 0.007526397705078125
ected 0.21044921875
▁cancer 0.638671875
▁cells 0.0299072265625
▁and 1.046875
▁reduce 1.3115234375
▁the 0.0030918121337890625
▁risk 0.08160400390625
▁of 0.00036215782165527344
▁rec 0.371826171875
urrence 0.006061553955078125
. 0.0276031494140625
▁For 5.2890625
▁instance 1.6689453125
, 0.00017368793487548828
▁a 0.2406005859375
▁trial 3.501953125
▁investig 3.99609375
ating 0.0085296630859375
▁the 0.79443359375
▁use 0.65966796875
▁of 0.0003361701965332031
▁p 1.474609375
emb 0.007244110107421875
rol 5.936622619628906e-05
iz 2.2292137145996094e-05
um 0.00024199485778808594
ab 2.396106719970703e-05
▁as 0.404541015625
▁adj 0.267333984375
uv 0.0006704330444335938
ant 4.315376281738281e-05
▁ther 0.0533447265625
apy 4.553794860839844e-05
▁for 1.82421875
▁patients 1.1279296875
▁with 0.05938720703125
▁stage 1.599609375
▁III 0.400634765625
▁mel 0.427001953125
an 3.635883331298828e-05
oma 0.00034880638122558594
▁demonstrated 2.212890625
▁a 0.34423828125
▁significantly 3.1875
▁increased 4.51171875
▁rec 3.01953125
urrence 0.0002079010009765625
- 0.031219482421875
free 0.00031304359436035156
▁surv 0.057952880859375
ival 1.5139579772949219e-05
▁among 6.6328125
▁the 2.58984375
▁treated 1.947265625
▁group 0.305908203125
▁compared 0.443115234375
▁to 0.0117340087890625
▁those 0.7392578125
▁receiving 0.97412109375
▁place 0.5009765625
bo 0.002315521240234375
. 0.1859130859375
▁These 1.3759765625
▁find 0.272216796875
ings 1.3113021850585938e-06
▁highlight 1.6396484375
▁the 0.00679779052734375
▁potential 0.3837890625
▁for 1.35546875
▁imm 0.89697265625
une 0.036590576171875
▁check 0.0057525634765625
point 0.00396728515625
▁in 0.0011119842529296875
hib 9.5367431640625e-07
itors 0.004375457763671875
▁to 0.177490234375
▁provide 3.20703125
▁long 0.91748046875
- 0.00035953521728515625
term 0.0989990234375
▁rem 1.1787109375
ission 0.01030731201171875
▁and 0.9541015625
▁improve 1.01953125
▁surv 0.79443359375
ival 0.0028514862060546875
▁rates 0.1285400390625
▁in 1.001953125
▁earlier 8.265625
▁stages 0.07501220703125
▁of 0.0025653839111328125
▁mel 0.07257080078125
an 6.687641143798828e-05
oma 5.7697296142578125e-05
. 0.268310546875
<0x0A> 0.01224517822265625
The 1.8505859375
▁imp 5.7109375
lications 0.01294708251953125
▁of 0.01103973388671875
▁these 0.5302734375
▁adv 0.40966796875
anc 0.06610107421875
ements 1.800060272216797e-05
▁are 1.44921875
▁prof 2.693359375
ound 2.6226043701171875e-06
. 1.2998046875
▁Pat 1.9296875
ients 0.0017671585083007812
▁diagn 2.123046875
osed 1.1205673217773438e-05
▁with 0.005619049072265625
▁mel 0.2174072265625
an 2.574920654296875e-05
oma 5.459785461425781e-05
▁at 4.3203125
▁various 3.84765625
▁stages 0.0036029815673828125
▁now 0.83837890625
▁have 0.0117034912109375
▁access 0.47314453125
▁to 0.0002562999725341797
▁more 2.072265625
▁effective 0.1414794921875
, 3.30078125
▁target 2.20703125
ed 0.0003376007080078125
, 4.51953125
▁and 0.0119476318359375
▁personal 1.357421875
ized 0.0098724365234375
▁treatment 1.109375
▁options 0.061248779296875
. 0.37353515625
▁Moreover 3.48828125
, 0.0001024007797241211
▁imm 2.92578125
une 0.06890869140625
▁check 0.002765655517578125
point 0.004817962646484375
▁in 0.001739501953125
hib 1.0728836059570312e-06
itors 0.004474639892578125
▁have 1.36328125
▁shown 2.443359375
▁potential 2.85546875
▁in 1.53125
▁extending 3.46484375
▁surv 0.82373046875
ival 0.002452850341796875
▁rates 0.64013671875
▁even 2.78515625
▁in 0.833984375
▁stage 6.21484375
▁IV 0.08697509765625
▁mel 0.384765625
an 1.3113021850585938e-05
oma 0.0016918182373046875
, 0.401123046875
▁histor 5.3515625
ically 8.344650268554688e-06
▁the 3.677734375
▁most 0.037261962890625
▁challeng 1.6044921875
ing 1.3232231140136719e-05
▁to 1.26953125
▁treat 0.0289154052734375
. 0.10284423828125
▁This 1.5908203125
▁remarkable 6.66015625
▁progress 0.313232421875
▁not 4.78125
▁only 0.0035839080810546875
▁prolong 6.97265625
s 0.0003266334533691406
▁the 1.44921875
▁lives 0.07000732421875
▁of 0.0018568038940429688
▁mel 2.3828125
an 7.867813110351562e-06
oma 1.1682510375976562e-05
▁patients 0.00441741943359375
▁but 0.1761474609375
▁also 0.0312347412109375
▁impro 1.92578125
ves 4.6133995056152344e-05
▁their 0.0711669921875
▁quality 0.06805419921875
▁of 0.00023853778839111328
▁life 0.00017511844635009766
▁by 1.2275390625
▁reducing 0.364501953125
▁the 0.4189453125
▁bur 1.7333984375
den 0.014190673828125
▁of 0.033233642578125
▁traditional 5.5703125
▁treat 2.310546875
ments 3.814697265625e-06
, 1.12890625
▁such 0.1982421875
▁as 8.487701416015625e-05
▁chem 0.16455078125
other 0.0006361007690429688
apy 0.00028443336486816406
. 1.2724609375
<0x0A> 0.10296630859375
The 1.990234375
▁case 0.345703125
▁of 0.0206298828125
▁Mr 0.004497528076171875
. 0.0022144317626953125
▁B 0.001476287841796875
▁exempl 3.80078125
ifies 0.00017559528350830078
▁the 0.1922607421875
▁transform 3.310546875
ative 0.07464599609375
▁impact 0.515625
▁of 0.060882568359375
▁imm 0.37939453125
une 0.00518035888671875
▁check 0.0016727447509765625
point 0.000980377197265625
▁in 0.0014743804931640625
hib 9.655952453613281e-06
itors 0.017913818359375
▁on 1.0146484375
▁mel 0.1669921875
an 8.58306884765625e-06
oma 1.7881393432617188e-05
▁treatment 0.13330078125
. 0.0232391357421875
▁Mr 0.414306640625
. 0.0007762908935546875
▁B 0.0009393692016601562
, 1.1064453125
▁diagn 4.28515625
osed 2.09808349609375e-05
▁with 0.0240325927734375
▁stage 0.2447509765625
▁IV 0.50146484375
▁mel 0.11376953125
an 1.4901161193847656e-05
oma 1.1920928955078125e-05
▁and 3.724609375
▁given 2.0546875
▁a 0.68603515625
▁ble 3.67578125
ak 4.017353057861328e-05
▁pro 0.018035888671875
gn 1.7881393432617188e-05
osis 0.00018978118896484375
, 0.1907958984375
▁comm 8.3125
enced 0.0012273788452148438
▁p 3.498046875
emb 0.0015363693237304688
rol 3.266334533691406e-05
iz 2.396106719970703e-05
um 0.00017547607421875
ab 9.179115295410156e-06
▁treatment 0.93115234375
. 0.8017578125
▁Rem 4.27734375
ark 0.0009284019470214844
ably 0.0006875991821289062
, 0.00011646747589111328
▁he 1.0439453125
▁experienced 1.0830078125
▁tum 5.33203125
or 0.06195068359375
▁regression 0.456298828125
, 1.3837890625
▁leading 2.96484375
▁to 0.0113983154296875
▁a 1.216796875
▁complete 0.53173828125
▁response 0.24365234375
▁and 1.6669921875
▁dur 3.671875
able 0.0008192062377929688
▁long 0.919921875
- 0.0004208087921142578
term 0.0011281967163085938
▁rem 0.01227569580078125
ission 0.0002046823501586914
. 0.090576171875
▁This 0.70458984375
▁example 5.09375
, 5.0859375
▁among 3.759765625
▁count 2.666015625
less 5.4836273193359375e-06
▁others 0.0286102294921875
, 0.037200927734375
▁demonstr 1.5498046875
ates 9.894371032714844e-06
▁the 0.1551513671875
▁potential 1.24609375
▁of 0.3642578125
▁imm 0.129150390625
une 0.00531768798828125
▁check 0.002559661865234375
point 0.0012302398681640625
▁in 0.0013713836669921875
hib 2.384185791015625e-07
itors 0.005474090576171875
▁in 2.296875
▁providing 1.9169921875
▁life 3.06640625
- 0.0004448890686035156
alter 2.5546875
ing 7.796287536621094e-05
▁out 1.056640625
comes 3.337860107421875e-06
▁for 0.15087890625
▁mel 0.9619140625
an 6.079673767089844e-06
oma 9.655952453613281e-06
▁patients 0.0005598068237304688
. 0.15625
<0x0A> 0.061065673828125
Con 1.759765625
clusion 0.014190673828125
: 0.0276947021484375
<0x0A> 4.109375
The 1.5244140625
▁adv 1.3505859375
anc 0.15234375
ements 1.9550323486328125e-05
▁in 0.08941650390625
▁mel 0.46484375
an 1.049041748046875e-05
oma 1.049041748046875e-05
▁treatment 0.024993896484375
▁through 1.9072265625
▁the 0.69140625
▁use 0.132568359375
▁of 0.000293731689453125
▁imm 0.01450347900390625
une 0.0013484954833984375
▁check 0.0006246566772460938
point 0.0010089874267578125
▁in 0.0004227161407470703
hib 5.960464477539062e-07
itors 0.0005731582641601562
▁and 0.089111328125
▁adj 0.040802001953125
uv 0.00014293193817138672
ant 0.0009136199951171875
▁ther 0.0011272430419921875
ap 0.060150146484375
ies 8.821487426757812e-06
▁have 0.88671875
▁revolution 1.3779296875
ized 0.0007748603820800781
▁patient 2.119140625
▁care 0.90576171875
. 0.29931640625
▁These 0.40869140625
▁ther 0.59716796875
ap 3.147125244140625e-05
ies 2.384185791015625e-06
▁offer 0.8466796875
▁new 1.4736328125
found 5.73828125
▁hope 0.01055908203125
▁for 1.0556640625
▁mel 2.275390625
an 5.9604644775390625e-06
oma 1.2516975402832031e-05
▁patients 0.01093292236328125
▁at 1.37109375
▁various 1.0908203125
▁stages 0.0038356781005859375
, 0.74365234375
▁including 2.201171875
▁those 0.1492919921875
▁with 0.37109375
▁advanced 0.388427734375
▁or 0.225830078125
▁met 0.011260986328125
ast 2.1576881408691406e-05
atic 0.0006184577941894531
▁disease 0.433349609375
. 0.42236328125
▁The 1.296875
▁case 1.18359375
▁of 0.014617919921875
▁Mr 0.0005445480346679688
. 0.0009465217590332031
▁B 0.0006389617919921875
▁exempl 2.958984375
ifies 0.0003421306610107422
▁the 0.09814453125
▁potential 1.703125
▁for 1.4013671875
▁long 1.185546875
- 0.00038051605224609375
term 0.01129150390625
▁rem 0.01044464111328125
ission 0.0024166107177734375
▁and 0.244384765625
▁improved 0.1392822265625
▁ch 10.703125
ances 0.0002505779266357422
▁of 0.203857421875
▁surv 0.08428955078125
ival 0.00434112548828125
. 1.4033203125
▁As 1.2548828125
▁research 1.2021484375
▁continues 0.70166015625
▁to 0.205810546875
▁enh 6.95703125
ance 3.933906555175781e-06
▁our 0.316650390625
▁understanding 0.00946044921875
▁of 0.012908935546875
▁these 1.3779296875
▁ther 0.497314453125
ap 4.851818084716797e-05
ies 1.9788742065429688e-05
, 0.5185546875
▁it 1.6396484375
▁is 0.042236328125
▁cru 2.91796875
cial 1.430511474609375e-05
▁to 0.2127685546875
▁ensure 1.322265625
▁access 2.14453125
ibility 1.0986328125
, 2.603515625
▁afford 0.52685546875
ability 0.002429962158203125
, 0.005374908447265625
▁and 0.0025768280029296875
▁expand 10.5625
▁their 2.08984375
▁use 0.60498046875
▁to 0.74462890625
▁further 2.703125
▁improve 0.517578125
▁the 2.328125
▁pro 3.470703125
gn 0.0005168914794921875
osis 0.044891357421875
▁and 2.70703125
▁quality 0.1387939453125
▁of 0.0006175041198730469
▁life 0.0009527206420898438
▁for 0.354736328125
▁mel 0.1756591796875
an 6.67572021484375e-06
oma 6.794929504394531e-06
▁patients 0.0016183853149414062
. 0.343994140625
